Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan: SMART Program 2002

Tsi Shu Huang, Susan Shin Jung Lee, Po Ren Hsueh, Hung Chin Tsai, Yao Shen Chen, Shue Ren Wann, Hsieh Shong Leu, Wen Chien Ko, Jing Jou Yan, Shi Zhi Yuan, Feng Yee Chang, Jang Jih Lu, Jen Hsien Wang, Hua Kung Wang, Yung Ching Liu

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background/purpose: To understand the resistance patterns of rapidly growing mycobacteria (RGM) in Taiwan, antimicrobial resistance of clinical isolates was determined as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Methods: During the period from January 2002 to December 2003, clinical isolates were collected from eight hospitals located on the west side of Taiwan and one reference laboratory. Broth microdilution minimum inhibitory concentrations of 11 antimicrobial agents were determined for 312 clinical isolates of RGM, including the Mycobacterium fortuitum group (110 isolates), Mycobacterium abscessus group (168 isolates), and Mycobacterium chelonae group (34 isolates). Results: Nearly all of the RGM were susceptible to amikacin and ofloxacin (≥ 90%) and resistant to doxycycline (<3% susceptible). Tobramycin showed similar in vitro activity against the M. fortuitum and M. chelonae (77%) groups, but was less active against the M. abscessus group (58%). Ciprofloxacin was active mainly against M. fortuitum (95%). Nearly all RGM were resistant to erythromycin and doxycycline. However, around half of the RGM isolates remained susceptible to minocycline (50-54%). Clarithromycin was active against the M. abscessus group (53% susceptible), with a high rate of resistance in the M. chelonae (38% susceptible) and M. fortuitum (15% susceptible) group. Cefoxitin was more active against the M. fortuitum group (65%) than the other two RGM (40-44%), and <40% of the RGM isolates remained susceptible to imipenem (21-38%). Conclusion: The resistance of RGM in Taiwan is not as high as previously reported (notably for tobramycin, ciprofloxacin and cefoxitin), but reduction in the susceptibility rates of clarithromycin and imipenem for the M. fortuitum and M. abscessus groups demonstrates the importance of in vitro susceptibility testing of clinically important isolates, as susceptibility may differ in different geographical areas, even regionally, and over time.

Original languageEnglish
Pages (from-to)281-287
Number of pages7
JournalJournal of the Formosan Medical Association = Taiwan yi zhi
Volume107
Issue number4
DOIs
Publication statusPublished - Apr 2008
Externally publishedYes

Fingerprint

Mycobacterium
Taiwan
Mycobacterium fortuitum
Mycobacterium chelonae
Cefoxitin
Tobramycin
Clarithromycin
Imipenem
Doxycycline
Ciprofloxacin
Minocycline
Ofloxacin
Amikacin
Microbial Sensitivity Tests
Erythromycin
Anti-Infective Agents

Keywords

  • Antibiotic resistance
  • Antibiotic susceptibility
  • Non-tuberculous mycobacterium
  • Rapidly growing mycobacteria
  • SMART

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan : SMART Program 2002. / Huang, Tsi Shu; Lee, Susan Shin Jung; Hsueh, Po Ren; Tsai, Hung Chin; Chen, Yao Shen; Wann, Shue Ren; Leu, Hsieh Shong; Ko, Wen Chien; Yan, Jing Jou; Yuan, Shi Zhi; Chang, Feng Yee; Lu, Jang Jih; Wang, Jen Hsien; Wang, Hua Kung; Liu, Yung Ching.

In: Journal of the Formosan Medical Association = Taiwan yi zhi, Vol. 107, No. 4, 04.2008, p. 281-287.

Research output: Contribution to journalArticle

Huang, TS, Lee, SSJ, Hsueh, PR, Tsai, HC, Chen, YS, Wann, SR, Leu, HS, Ko, WC, Yan, JJ, Yuan, SZ, Chang, FY, Lu, JJ, Wang, JH, Wang, HK & Liu, YC 2008, 'Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan: SMART Program 2002', Journal of the Formosan Medical Association = Taiwan yi zhi, vol. 107, no. 4, pp. 281-287. https://doi.org/10.1016/S0929-6646(08)60088-1
Huang, Tsi Shu ; Lee, Susan Shin Jung ; Hsueh, Po Ren ; Tsai, Hung Chin ; Chen, Yao Shen ; Wann, Shue Ren ; Leu, Hsieh Shong ; Ko, Wen Chien ; Yan, Jing Jou ; Yuan, Shi Zhi ; Chang, Feng Yee ; Lu, Jang Jih ; Wang, Jen Hsien ; Wang, Hua Kung ; Liu, Yung Ching. / Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan : SMART Program 2002. In: Journal of the Formosan Medical Association = Taiwan yi zhi. 2008 ; Vol. 107, No. 4. pp. 281-287.
@article{52a1501e6fc140fb8fa0df297f9fc411,
title = "Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan: SMART Program 2002",
abstract = "Background/purpose: To understand the resistance patterns of rapidly growing mycobacteria (RGM) in Taiwan, antimicrobial resistance of clinical isolates was determined as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Methods: During the period from January 2002 to December 2003, clinical isolates were collected from eight hospitals located on the west side of Taiwan and one reference laboratory. Broth microdilution minimum inhibitory concentrations of 11 antimicrobial agents were determined for 312 clinical isolates of RGM, including the Mycobacterium fortuitum group (110 isolates), Mycobacterium abscessus group (168 isolates), and Mycobacterium chelonae group (34 isolates). Results: Nearly all of the RGM were susceptible to amikacin and ofloxacin (≥ 90{\%}) and resistant to doxycycline (<3{\%} susceptible). Tobramycin showed similar in vitro activity against the M. fortuitum and M. chelonae (77{\%}) groups, but was less active against the M. abscessus group (58{\%}). Ciprofloxacin was active mainly against M. fortuitum (95{\%}). Nearly all RGM were resistant to erythromycin and doxycycline. However, around half of the RGM isolates remained susceptible to minocycline (50-54{\%}). Clarithromycin was active against the M. abscessus group (53{\%} susceptible), with a high rate of resistance in the M. chelonae (38{\%} susceptible) and M. fortuitum (15{\%} susceptible) group. Cefoxitin was more active against the M. fortuitum group (65{\%}) than the other two RGM (40-44{\%}), and <40{\%} of the RGM isolates remained susceptible to imipenem (21-38{\%}). Conclusion: The resistance of RGM in Taiwan is not as high as previously reported (notably for tobramycin, ciprofloxacin and cefoxitin), but reduction in the susceptibility rates of clarithromycin and imipenem for the M. fortuitum and M. abscessus groups demonstrates the importance of in vitro susceptibility testing of clinically important isolates, as susceptibility may differ in different geographical areas, even regionally, and over time.",
keywords = "Antibiotic resistance, Antibiotic susceptibility, Non-tuberculous mycobacterium, Rapidly growing mycobacteria, SMART",
author = "Huang, {Tsi Shu} and Lee, {Susan Shin Jung} and Hsueh, {Po Ren} and Tsai, {Hung Chin} and Chen, {Yao Shen} and Wann, {Shue Ren} and Leu, {Hsieh Shong} and Ko, {Wen Chien} and Yan, {Jing Jou} and Yuan, {Shi Zhi} and Chang, {Feng Yee} and Lu, {Jang Jih} and Wang, {Jen Hsien} and Wang, {Hua Kung} and Liu, {Yung Ching}",
year = "2008",
month = "4",
doi = "10.1016/S0929-6646(08)60088-1",
language = "English",
volume = "107",
pages = "281--287",
journal = "Journal of the Formosan Medical Association",
issn = "0929-6646",
publisher = "Elsevier Science Publishers B.V.",
number = "4",

}

TY - JOUR

T1 - Antimicrobial resistance of rapidly growing mycobacteria in Western Taiwan

T2 - SMART Program 2002

AU - Huang, Tsi Shu

AU - Lee, Susan Shin Jung

AU - Hsueh, Po Ren

AU - Tsai, Hung Chin

AU - Chen, Yao Shen

AU - Wann, Shue Ren

AU - Leu, Hsieh Shong

AU - Ko, Wen Chien

AU - Yan, Jing Jou

AU - Yuan, Shi Zhi

AU - Chang, Feng Yee

AU - Lu, Jang Jih

AU - Wang, Jen Hsien

AU - Wang, Hua Kung

AU - Liu, Yung Ching

PY - 2008/4

Y1 - 2008/4

N2 - Background/purpose: To understand the resistance patterns of rapidly growing mycobacteria (RGM) in Taiwan, antimicrobial resistance of clinical isolates was determined as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Methods: During the period from January 2002 to December 2003, clinical isolates were collected from eight hospitals located on the west side of Taiwan and one reference laboratory. Broth microdilution minimum inhibitory concentrations of 11 antimicrobial agents were determined for 312 clinical isolates of RGM, including the Mycobacterium fortuitum group (110 isolates), Mycobacterium abscessus group (168 isolates), and Mycobacterium chelonae group (34 isolates). Results: Nearly all of the RGM were susceptible to amikacin and ofloxacin (≥ 90%) and resistant to doxycycline (<3% susceptible). Tobramycin showed similar in vitro activity against the M. fortuitum and M. chelonae (77%) groups, but was less active against the M. abscessus group (58%). Ciprofloxacin was active mainly against M. fortuitum (95%). Nearly all RGM were resistant to erythromycin and doxycycline. However, around half of the RGM isolates remained susceptible to minocycline (50-54%). Clarithromycin was active against the M. abscessus group (53% susceptible), with a high rate of resistance in the M. chelonae (38% susceptible) and M. fortuitum (15% susceptible) group. Cefoxitin was more active against the M. fortuitum group (65%) than the other two RGM (40-44%), and <40% of the RGM isolates remained susceptible to imipenem (21-38%). Conclusion: The resistance of RGM in Taiwan is not as high as previously reported (notably for tobramycin, ciprofloxacin and cefoxitin), but reduction in the susceptibility rates of clarithromycin and imipenem for the M. fortuitum and M. abscessus groups demonstrates the importance of in vitro susceptibility testing of clinically important isolates, as susceptibility may differ in different geographical areas, even regionally, and over time.

AB - Background/purpose: To understand the resistance patterns of rapidly growing mycobacteria (RGM) in Taiwan, antimicrobial resistance of clinical isolates was determined as part of the SMART (Surveillance from Multicenter Antimicrobial Resistance in Taiwan) program. Methods: During the period from January 2002 to December 2003, clinical isolates were collected from eight hospitals located on the west side of Taiwan and one reference laboratory. Broth microdilution minimum inhibitory concentrations of 11 antimicrobial agents were determined for 312 clinical isolates of RGM, including the Mycobacterium fortuitum group (110 isolates), Mycobacterium abscessus group (168 isolates), and Mycobacterium chelonae group (34 isolates). Results: Nearly all of the RGM were susceptible to amikacin and ofloxacin (≥ 90%) and resistant to doxycycline (<3% susceptible). Tobramycin showed similar in vitro activity against the M. fortuitum and M. chelonae (77%) groups, but was less active against the M. abscessus group (58%). Ciprofloxacin was active mainly against M. fortuitum (95%). Nearly all RGM were resistant to erythromycin and doxycycline. However, around half of the RGM isolates remained susceptible to minocycline (50-54%). Clarithromycin was active against the M. abscessus group (53% susceptible), with a high rate of resistance in the M. chelonae (38% susceptible) and M. fortuitum (15% susceptible) group. Cefoxitin was more active against the M. fortuitum group (65%) than the other two RGM (40-44%), and <40% of the RGM isolates remained susceptible to imipenem (21-38%). Conclusion: The resistance of RGM in Taiwan is not as high as previously reported (notably for tobramycin, ciprofloxacin and cefoxitin), but reduction in the susceptibility rates of clarithromycin and imipenem for the M. fortuitum and M. abscessus groups demonstrates the importance of in vitro susceptibility testing of clinically important isolates, as susceptibility may differ in different geographical areas, even regionally, and over time.

KW - Antibiotic resistance

KW - Antibiotic susceptibility

KW - Non-tuberculous mycobacterium

KW - Rapidly growing mycobacteria

KW - SMART

UR - http://www.scopus.com/inward/record.url?scp=43449084046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43449084046&partnerID=8YFLogxK

U2 - 10.1016/S0929-6646(08)60088-1

DO - 10.1016/S0929-6646(08)60088-1

M3 - Article

C2 - 18445541

AN - SCOPUS:43449084046

VL - 107

SP - 281

EP - 287

JO - Journal of the Formosan Medical Association

JF - Journal of the Formosan Medical Association

SN - 0929-6646

IS - 4

ER -